000			02257nam a22004575i 4500
001			978-3-319-00978-0
003			DE-He213
005			20140220082507.0
007			cr nn 008mamaa
008			131107s2014 gw | s |||| 0|eng d
020			_a9783319009780 _9978-3-319-00978-0
024	7		_a10.1007/978-3-319-00978-0 _2doi
050		4	_aRM281
050		4	_aQR189-189.5
072		7	_aMJCM _2bicssc
072		7	_aMED044000 _2bisacsh
082	0	4	_a615.372 _223
100	1		_aGiese, Matthias. _eeditor.
245	1	0	_aMolecular Vaccines _h[electronic resource] : _bFrom Prophylaxis to Therapy - Volume 2 / _cedited by Matthias Giese.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2014.
300			_aXXVIII, 870 p. 98 illus., 74 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aNon-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.
520			_aThis title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.
650		0	_aMedicine.
650		0	_aImmunology.
650		0	_aVaccines.
650	1	4	_aBiomedicine.
650	2	4	_aVaccine.
650	2	4	_aImmunology.
650	2	4	_aMolecular Medicine.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783319009773
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-319-00978-0
912			_aZDB-2-SBL
999			_c92567 _d92567